MDS’s cancer immunotherapy Keytruda has again topped the rank in pharmaceutical sales this year. Its increase in sales has been reduced somewhat due to the price cut disposition that followed Keytruda's reimbursement expansion, still, the drug was able to maintain its lead for the 9th consecutive quarter. Also, new drugs from multinational pharmaceutical companies, such as Plavix, Opdivo, Prolia, and Dupixent showed strength this quarter.

According to the market research institution IQVIA on the 20th, Keytruda made the most among pharmaceuticals in Korea in the first quarter of this year, recording sales of ₩40.4 billion. Although the amount has decreased 8.4% YoY, still, the drug was able to mainta